Next earnings date: 21 Oct 2025
Boston Scientific Corporation – NYSE:BSX
Boston Scientific stock price today
$103.94
+13.28
+14.65%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 25 minutes
Boston Scientific stock price monthly change
+16.70%
month
Boston Scientific stock price quarterly change
+16.70%
quarter
Boston Scientific stock price yearly change
+61.83%
year
Boston Scientific key metrics
Market Cap | 131.00B |
Enterprise value | 80.68B |
P/E | 112.73 |
EV/Sales | 6.36 |
EV/EBITDA | 30.58 |
Price/Sales | 5.73 |
Price/Book | 4.13 |
PEG ratio | -3.42 |
EPS | 1.2 |
Revenue | 14.70B |
EBITDA | 3.61B |
Income | 1.77B |
Revenue Q/Q | 13.77% |
Revenue Y/Y | 12.74% |
Profit margin | 5.39% |
Oper. margin | 14.86% |
Gross margin | 68.52% |
EBIT margin | 14.86% |
EBITDA margin | 24.59% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBoston Scientific stock price history
Boston Scientific stock forecast
Boston Scientific financial statements
| Jun 2023 | 3.59B | 270M | 7.5% |
|---|---|---|---|
| Sep 2023 | 3.52B | 504M | 14.29% |
| Dec 2023 | 3.72B | 505M | 13.56% |
| Mar 2024 | 3.85B | 492M | 12.76% |
| Sep 2025 | 4.23B | 934.12M | 22.07% |
|---|---|---|---|
| Oct 2025 | 4.34B | 967.16M | 22.27% |
| Dec 2025 | 4.59B | 1.05B | 22.94% |
| Mar 2026 | 4.36B | 1.01B | 23.12% |
Analysts Price target
Financials & Ratios estimates
| 2024-10-23 | 0.588 | 0.63 |
|---|
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | 0.06% |
| 2021 | 0.09% |
| 2022 | 0.08% |
| 2023 | 0.03% |
| Jun 2023 | 33601000000 | 15.11B | 44.99% |
|---|---|---|---|
| Sep 2023 | 34043000000 | 14.91B | 43.81% |
| Dec 2023 | 35136000000 | 15.60B | 44.42% |
| Mar 2024 | 36669000000 | 16.50B | 45% |
| Jun 2023 | 658M | -840M | 43M |
|---|---|---|---|
| Sep 2023 | 698M | -197M | 16M |
| Dec 2023 | 957M | -1.05B | 15M |
| Mar 2024 | 164M | -285M | 1.56B |
Boston Scientific alternative data
| Sep 2023 | 45,000 |
|---|---|
| Oct 2023 | 45,000 |
| Nov 2023 | 45,000 |
| Dec 2023 | 45,000 |
| Jan 2024 | 45,000 |
| Feb 2024 | 45,000 |
| Mar 2024 | 48,000 |
| Apr 2024 | 48,000 |
| May 2024 | 48,000 |
| Jun 2024 | 48,000 |
| Jul 2024 | 48,000 |
Boston Scientific other data
57.64%
-30.73%
of BSX is owned by hedge funds
651
-214
829.06M
-437.95M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 68935 |
| Feb 2024 | 0 | 21278 |
| Mar 2024 | 0 | 21489 |
| Apr 2024 | 0 | 33152 |
| May 2024 | 0 | 119260 |
| Jun 2024 | 0 | 6983 |
| Jul 2024 | 0 | 6983 |
| Aug 2024 | 0 | 35127 |
| Sep 2024 | 0 | 169760 |
| Oct 2024 | 0 | 302287 |
| Nov 2024 | 0 | 220564 |
| Dec 2024 | 0 | 6983 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | CARRUTHERS WENDY officer: EVP, Hum.. | Common Stock | 1,197 | $24.55 | $29,386 | ||
Option | CARRUTHERS WENDY officer: EVP, Hum.. | Common Stock | 3,066 | $17.26 | $52,919 | ||
Sale | CARRUTHERS WENDY officer: EVP, Hum.. | Common Stock | 6,983 | $90.78 | $633,917 | ||
Option | CARRUTHERS WENDY officer: EVP, Hum.. | Stock Option (Right to Buy) | 1,197 | $24.55 | $29,386 | ||
Option | CARRUTHERS WENDY officer: EVP, Hum.. | Stock Option (Right to Buy) | 3,066 | $17.26 | $52,919 | ||
Sale | WOODWORTH EMILY officer: SVP, Global Controller.. | Common Stock | 1,336 | $90.65 | $121,106 | ||
Option | BUTCHER ARTHUR C officer: EVP& Grp Pres, MedSurg.. | Common Stock | 1,009 | $17.26 | $17,415 | ||
Option | BUTCHER ARTHUR C officer: EVP& Grp Pres, MedSurg.. | Common Stock | 3,177 | $22.71 | $72,150 | ||
Option | BUTCHER ARTHUR C officer: EVP& Grp Pres, MedSurg.. | Stock Option (Right to Buy) | 3,177 | $22.71 | $72,150 | ||
Option | BUTCHER ARTHUR C officer: EVP& Grp Pres, MedSurg.. | Stock Option (Right to Buy) | 1,009 | $17.26 | $17,415 |
| Patent |
|---|
Application Filling date: 23 Mar 2020 Issue date: 19 May 2022 |
Application Filling date: 1 May 2020 Issue date: 13 Aug 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 24 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 31 Jan 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 26 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 27 Jul 2023 | Q2 2023 Earnings Call Transcript |
Boston Scientific Corporation Is Expensive But Worth It
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
GE HealthCare: Near-Term Margin Headwinds Priced In, Long-Term Growth Driven By New Products And M&As
LeMaitre Vascular: Scaling Nicely As Global Demand Builds
NervGen Pharma: Risky, Yet Promising With Big Upside
Boston Scientific: Old, Reliable; Buy For Their Consistent Growth
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Abbott Laboratories: Strong Q4 Results And Bullish Outlook
Boston Scientific Corporation: Solid Financials And Upward Continuation
-
What's the price of Boston Scientific stock today?
One share of Boston Scientific stock can currently be purchased for approximately $103.94.
-
When is Boston Scientific's next earnings date?
Boston Scientific Corporation is estimated to report earnings on Tuesday, 21 Oct 2025.
-
Does Boston Scientific pay dividends?
No, Boston Scientific does not pay dividends.
-
How much money does Boston Scientific make?
Boston Scientific has a market capitalization of 131.00B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.29% to 14.24B US dollars. Boston Scientific earned 1.59B US dollars in net income (profit) last year or $0.63 on an earnings per share basis.
-
What is Boston Scientific's stock symbol?
Boston Scientific Corporation is traded on the NYSE under the ticker symbol "BSX".
-
What is Boston Scientific's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Boston Scientific?
Shares of Boston Scientific can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Boston Scientific's key executives?
Boston Scientific's management team includes the following people:
- Mr. Michael F. Mahoney Chairman, Pres & Chief Executive Officer(age: 60, pay: $2,230,000)
- Mr. Daniel J. Brennan Executive Vice President & Chief Financial Officer(age: 59, pay: $1,040,000)
- Mr. Joseph M. Fitzgerald Executive Vice President & Pres of Interventional Cardiology(age: 61, pay: $1,010,000)
- Mr. Edward F. Mackey Executive Vice President of Global Operations(age: 62, pay: $909,740)
- Mr. Jeffrey B. Mirviss Executive Vice President & Pres of Peripheral Interventions(age: 59, pay: $875,740)
-
How many employees does Boston Scientific have?
As Jul 2024, Boston Scientific employs 48,000 workers.
-
When Boston Scientific went public?
Boston Scientific Corporation is publicly traded company for more then 33 years since IPO on 19 May 1992.
-
What is Boston Scientific's official website?
The official website for Boston Scientific is bostonscientific.com.
-
Where are Boston Scientific's headquarters?
Boston Scientific is headquartered at 300 Boston Scientific Way, Marlborough, MA.
-
How can i contact Boston Scientific?
Boston Scientific's mailing address is 300 Boston Scientific Way, Marlborough, MA and company can be reached via phone at +508 6834000.
Boston Scientific company profile:
Boston Scientific Corporation
bostonscientific.comExchange:
NYSE
Full time employees:
48,000
Industry:
Medical - Devices
Sector:
Healthcare
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
300 Boston Scientific Way
Marlborough, MA 01752-1234
Marlborough, MA 01752-1234
CIK: 0000885725
ISIN: US1011371077
CUSIP: 101137107
